Methylation of CpG islands of p16INK4a and cyclinD1 overexpression associated with progression of intraductal proliferative lesions of the breast

Human Pathology

Volumn 39, Issue 11, 2008, Pages 1637-1646

  Liu, Tieju ^a   Niu, Yun ^a   Feng, Yumei ^a   Niu, Ruifang ^a   Yu, Yong ^a   Lv, Ajuan ^a   Yang, Yi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Intraductal proliferative lesions; Methylation; MethyLight; p16INK4a

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DIFFERENTIAL DIAGNOSIS; DNA METHYLATION; DNA MODIFICATION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTRADUCTAL CARCINOMA; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; TUMOR SUPPRESSOR GENE;

BREAST; BREAST NEOPLASMS; CPG ISLANDS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; HUMANS;

EID: 53849141472     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.04.001     Document Type: Article

References (35)

1. Jie G., Zhixiang S., Lei S., Hesheng L., and Xiaojun T. Relationship between expression and methylation status of p16(INK4a) and the proliferative activity of different areas' tumour cells in human colorectal cancer. Int J Clin Pract 61 (2007) 1523-1529
2. Kraunz K.S., Hsiung D., McClean M.D., et al. Dietary folate is associated with p16(INK4A) methylation in head and neck squamous cell carcinoma. Int J Cancer 119 (2006) 1553-1557
3. Lehmann U., Länger F., Feist H., Glöckner S., Hasemeier B., and Kreipe H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol 160 (2002) 605-612
4. Cánepa E.T., Scassa M.E., Ceruti J.M., et al. INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59 (2007) 419-426
5. McDermott K.M., Zhang J., Holst C.R., Kozakiewicz B.K., Singla V., and Tlsty T.D. p16(INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 4 (2006) e51
6. Roy P.G., and Thompson A.M. Cyclin D1 and breast cancer. Breast 15 (2006) 718-727
7. Tavassoli F.A., and Devilee P. The WHO classification of tumors of the breast and female genital organs (2003), Editors IARC Press, Lyon
8. Viale G. Histopathology of primary breast cancer. Breast 14 (2005) 487-492
9. Moriya T., Hirakawa H., Suzuki T., Sasano H., and Ohuchi N. Ductal carcinoma in situ and related lesions of the breast: recent advances in pathology practice. Breast Cancer 11 (2004) 325-333
10. Moriya T., Kasajima A., Ishida K., et al. New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol 39 (2006) 8-13
11. Lacroix-Triki M., Mery E., Voigt J.J., Istier L., and Rochaix P. Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody. Virchows Arch 442 (2003) 548-554
12. Denoux Y., Lebeau C.H., Michels J.J., and Chasle J. Double immunohistochemical labeling technique applied to different types of cytokeratins in epithelial proliferations of the breast. Biotech Histochem 78 (2003) 23-26
13. Feinberg A.P., and Tycko B. The history of cancer epigenetics. Nat Rev Cancer 4 (2004) 143-153
14. Nielsen N.H., Roos G., Emdin S.O., and Landberg G. Methylation of the p16(Ink4a) tumor suppressor gene 5'-CpG island in breast cancer. Cancer Lett 163 (2001) 59-69
15. Miyamoto K., and Ushijima T. Diagnostic and therapeutic applications of epigenetics. Jpn J Clin Oncol 35 (2005) 293-301
16. Eads C.A., Danenberg K.D., Kawakami K., et al. Methylight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28 (2000) E32
17. Ogino S., Kawasaki T., Brahmandam M., et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 8 (2006) 209-217
18. Widschwendter M., Siegmund K.D., Müller H.M., et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64 (2004) 3807-3813
19. Eads C.A., Lord R.V., Kurumboor S.K., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 60 (2000) 5021-5026
20. Eads C.A., Lord R.V., Wickramasinghe K., et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 61 (2001) 3410-3418
21. Ogino S., Cantor M., Kawasaki T., et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterized by quantitative DNA methylation analysis and prospective cohort studies. Gut 55 (2006) 1000-1006
22. Tsujie M., Yamamoto H., Tomita N., et al. Expression of tumor suppressor gene p16(INK4) products in primary gastric cancer. Oncology 58 (2000) 126-136
23. Umekita Y., Ohi Y., Sagara Y., and Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 98 (2002) 415-418
24. Geradts J., Wilentz R.E., and Roberts H. Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression. Mod Pathol 14 (2001) 1162-1168
25. Geradts J., and Ingram C.D. Abnormal expression of cell cycle regulatory proteins in ductal and lobular carcinomas of the breast. Mod Pathol 13 (2000) 945-953
26. Niu Y., Fu X., Lv A., Fan Y., and Wang Y. Potential markers predicting distant metastasis in axillary node-negative breast carcinoma. Int J Cancer 98 (2002) 754-760
27. Wu M.Y., Zhuang C.X., Yang H.X., and Liang Y.R. Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: an immunohistochemical and in situ hybridization study. World J Gastroenterol 10 (2004) 476-480
28. Wu C.T., and Morris J.R. Genes, genetics and epigenetics: a correspondence. Science 293 (2001) 1103-1105
29. Ota N., Kawakami K., Okuda T., et al. Prognostic significance of p16 (INK4a)hypermethylation in non-small cell lung cancer is evident by quantitative DNA methylation analysis. Anticancer Res 26 (2006) 3729-3732
30. Kim B.N., Yamamoto H., Ikeda K., et al. Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 26 (2005) 1217-1226
31. Ogino S., Kawasaki T., Kirkner G.J., Ohnishi M., and Fuchs C.S. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high. BMC Cancer 7 (2007) 72
32. Ogino S., Brahmandam M., Kawasaki T., Kirkner G.J., Loda M., and Fuchs C.S. Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Neoplasia 8 (2006) 458-464
33. Zeschnigk M., Böhringer S., Price E.A., Onadim Z., Masshöfer L., and Lohmann D.R. A novel real-time PCR assay for quantitative analysis of methylated alleles (QAMA): analysis of the retinoblastoma locus. Nucleic Acids Res 32 (2004) e125
34. Di Vinci A., Perdelli L., Banelli B., et al. p16 (INK4a) promoter methylation and protein expression in breast fibroadenoma and carcinoma. Int J Cancer 114 (2005) 414-421
35. Putti T.C., Pinder S.E., Elston C.W., Lee A.H., and Ellis I.O. Breast pathology practice: most common problems in a consultation service. Histopathology 47 (2005) 445-457